Bart Henderson, MBA
Chief Executive Officer and Co-Founder
Mr. Henderson is Chief Executive Officer and a co-founder of Torque. He previously was President and Founder of Rhythm and its subsidiary, Motus (acquired by Allergan), with responsibility for business development, finance, marketing, and manufacturing operations. Prior to that, he was Entrepreneur-in-Residence at MPM Capital; Chief Business Officer of Radius, where he was a founding employee; Head of Sales and Marketing at Vertex; Head of Business Development at Microbia (now Ironwood Pharmaceuticals); and also held marketing management positions at Amgen and Merck. Mr. Henderson received an MBA from Dartmouth’s Tuck School of Business and a BA from Amherst College.

Ulrik B. Nielsen, PhD
President and Co-Founder
Dr. Nielsen is President and a co-founder of Torque. He was previously a founder of Merrimack (NASDAQ:MACK), where he served as the Chief Scientific Officer until 2015 and remains on the board of directors. At Merrimack, Dr. Nielsen was responsible for R&D and the early phases of clinical development. He also served as Chief Executive Officer of Silver Creek Pharmaceuticals, a majority-owned subsidiary of Merrimack, from July 2010 to March 2014. Dr. Nielsen holds a PhD in Molecular Biology from the University of Copenhagen and did research at UCSF and MIT.

Thomas Lars Andresen, PhD
Head of Discovery and Co-Founder
Dr. Andresen is a co-founder and leads discovery at Torque. Since 2007, he has been a Professor and group leader of the Colloids and Biological Interfaces group at DTU Nanotech, and was head of the DTU Center for Nanomedicine and Theranostics. Dr. Andresen is an expert in biomaterial engineering and drug delivery. He founded NANOVI in 2011 and was formerly Head of R&D at LiPlasome Pharma. Dr. Andresen has strong experience in the fields of organic chemistry, biophysics, nanotechnology and nanomedicine, drug delivery, and cancer biology, and is an author on more than 100 research or review articles and multiple patent applications.

Becker Hewes, MD
Chief Medical Officer
Dr. Hewes is Chief Medical Officer of Torque. He has more than 10 years of industry experience, most recently serving as an Executive Medical Director at Novartis Institute for Biomedical Research, where he was responsible for a wide array of clinical and preclinical immuno-oncology compounds as well as the early clinical development of ribociclib in breast cancer. Dr. Hewes has held positions within early oncology clinical development at both Genzyme and AstraZeneca. At Wyeth Oncology, he was responsible for the supplemental NDA filing for Torisel in Mantle Cell Lymphoma as well as the phase 1-3 program for bosutinib that resulted in FDA approval in chronic myeloid leukemia. Prior to joining industry, Dr. Hewes’ research focused on preclinical models of anti-tumor immunity at the Emory-Yerkes Vaccine Center.

Bruce Weaver, PhD
Vice President of Biologics Manufacturing
Dr. Weaver leads manufacturing at Torque. He has 20 years experience in recombinant protein process development at VaxInnate, Laureate Pharma, and Unigene Laboratories, where he led their downstream groups. Mr. Weaver received a BS in Chemical Engineering from Bucknell University and holds master’s degrees from Tufts University and Rutgers University.

Jennifer Camacho, JD
Chief Legal Officer
Ms. Camacho is the Chief Legal Officer at Torque. Previously, she was the Chief Legal Officer for Gen9 until its acquisition by Ginkgo Bioworks in January 2017. She is a member of the Patent Public Advisory Committee to the U.S. Patent and Trademark Office, appointed by the U.S. Secretary of Commerce in 2015. Prior to joining Gen9, Ms. Camacho was a partner in Greenberg Traurig, LLP, and Proskauer Rose, LLP. She holds a JD from Boston College Law School.

Back to Top